Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
14.80
+0.43 (2.99%)
At close: May 12, 2025, 4:00 PM
14.70
-0.10 (-0.68%)
After-hours: May 12, 2025, 6:18 PM EDT
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 13 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 33.92, with a low estimate of 24 and a high estimate of 45. The average target predicts an increase of 129.19% from the current stock price of 14.80.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Denali Therapeutics stock from 15 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 8 | 8 | 7 |
| Buy | 3 | 5 | 5 | 7 | 7 | 7 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 13 | 13 | 16 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Baird | Baird | Buy Maintains $30 → $29 | Buy | Maintains | $30 → $29 | +95.95% | May 8, 2025 |
| Wedbush | Wedbush | Buy Maintains $32 → $30 | Buy | Maintains | $32 → $30 | +102.70% | May 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $80 → $32 | Strong Buy | Maintains | $80 → $32 | +116.22% | May 7, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $30 → $28 | Strong Buy | Maintains | $30 → $28 | +89.19% | Mar 10, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $41 → $33 | Buy | Initiates | $41 → $33 | +122.97% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
23.65M
Revenue Next Year
114.51M
from 23.65M
Increased by 384.25%
EPS This Year
-2.89
from -2.57
EPS Next Year
-2.74
from -2.89
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.3M | 298.3M | 820.0M | ||
| Avg | 23.6M | 114.5M | 276.1M | ||
| Low | n/a | 24.8M | 105.8M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,161.6% | 616.1% | ||
| Avg | - | 384.2% | 141.1% | ||
| Low | - | 5.0% | -7.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.30 | -1.73 | -0.87 | ||
| Avg | -2.89 | -2.74 | -2.41 | ||
| Low | -3.26 | -3.57 | -3.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.